Reviewer’s report

Title: Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review

Version: 0 Date: 24 Nov 2017

Reviewer: Antonia Chen

Reviewer's report:

Lines 29-31 - Please list the topics in the order they are presented in the paper (e.g. infectious, cardiac and thromboembolic adverse events)

Line 76-78 - The Authors should define the dosage of glucocorticoid that fits into this recommendation:

" The panel recommends administering the usual daily dose of glucocorticoid rather than supraphysiologic "stress dose steroids" on the day of THA or TKA, specifically for adults receiving glucocorticoids for treatment of their rheumatic condition"

Lines 87 and 110 - MI defined twice when it only needs to be defined once

For the section on "Major Acute Cardiac Events" - it may be beneficial to create a "practical" section, where the authors narrate what they recommend for these patients prior to surgery (e.g. screening, risk stratification, laboratory markers, smoking cessation, etc.) and if it differs for various groups of patients (e.g. RA, SLE, etc)

The authors recommend utilizing warfarin in patients with antiphospholipid antibody syndrome (APS). Can the authors please suggest VTE prophylaxis in TJA patients for all other conditions (e.g. RA, SLE, etc)? A table may be beneficial to help guide readers.

Quality of written English

Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal